Prospective randomized trial of everolimus- and zotarolimus-eluting stents for treatment of unprotected left main coronary artery disease: ISAR-LEFT-MAIN-2.
Phase of Trial: Phase IV
Latest Information Update: 01 Jan 2017
At a glance
- Drugs Everolimus (Primary) ; Zotarolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
- Focus Therapeutic Use
- Acronyms ISAR-LEFT-MAIN-2
- 08 Aug 2013 Primary endpoint 'Major-adverse-cardiac-event-rate' has not been met according to results published in the Journal of the American College of Cardiology.
- 08 Aug 2013 Results published in the Journal of the American College of Cardiology.
- 04 Jan 2012 Additional lead trial investigator identified and actual patient number is 650 as reported by ClinicalTrials.gov.